We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
- Authors
Vredenburgh, James J; Desjardins, Annick; Herndon, James E, 2nd; Marcello, Jennifer; Reardon, David A; Quinn, Jennifer A; Rich, Jeremy N; Sathornsumetee, Sith; Gururangan, Sridharan; Sampson, John; Wagner, Melissa; Bailey, Leighann; Bigner, Darell D; Friedman, Allan H; Friedman, Henry S
- Abstract
The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 30, p4722
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.12.2440